Half: A prospective Multi-Centre phase II clinical trial
evaluating the efficacy and safety of tyrosine kinase
inhibitors' discontinuation after two-step dose reduction in
patients with chronic myeloid leukemia in deep molecular
remission.

a 2021

Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.

ŽÁČKOVÁ, Daniela; Edgar FABER; L. STEJSKAL; M. KARAS; Petra BĚLOHLÁVKOVÁ et al.

Základní údaje

Originální název

Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.

Autoři

Vydání

63rd ASH Annual Meeting and Exposition in Blood, 2021

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 25.669

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/21:00125334

Organizační jednotka

Lékařská fakulta

ISSN

DOI

https://doi.org/10.1182/blood-2021-146221

UT WoS

000736413906171

Klíčová slova anglicky

Tyrosine Kinase Inhibitors' Discontinuation; Two-Step Dose Reduction; Chronic Myeloid Leukemia

Štítky

rivok

Příznaky

Mezinárodní význam

Změněno: 3. 4. 2023 08:49, Mgr. Tereza Miškechová

Anotace

V originále

Treatment-free remission (TFR) has become a new treatment goal for chronic myeloid leukemia (CML) patients. However, usually abrupt tyrosine kinase inhibitors (TKIs) therapy discontinuation has been successful only in about half of eligible patients and it can cause burdening TKI withdrawal syndrome (TWS) in about 30% of them. Moreover, any robust clinical or biological factor predictive for successful TFR has not been identified yet. On top of that, sustainable deep molecular response (DMR) as the main prerequisite for TKI discontinuation attempt is achieved only in 20-40% of patients. The majority of CML patients, therefore, need to be treated with the effective and well-tolerated drug for a long time or even life-long.

Návaznosti

MUNI/A/1595/2020, interní kód MU

Název: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VIII (Akronym: VýDiTeHeMa VIII)

Investor: Masarykova univerzita, Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VIII

90128, velká výzkumná infrastruktura

Název: CZECRIN III

Citovat

ŽÁČKOVÁ, Daniela; Edgar FABER; L. STEJSKAL; M. KARAS; Petra BĚLOHLÁVKOVÁ; H. KLAMOVÁ; O. ČERNÁ; Eduard CMUNT; Petra ČIČÁTKOVÁ; Lukáš SEMERÁD; Tomáš HORŇÁK; Anežka KVETKOVÁ; Jiřina PROCHÁZKOVÁ; Jitka RYCHLÍČKOVÁ; Radka ŠTĚPÁNOVÁ; Adam SVOBODNÍK; Kateřina MACHOVÁ POLÁKOVÁ; Ivana JEŽÍŠKOVÁ; Tomáš JURČEK; Marek BORSKÝ; Ondřej WIEWIORKA; Regina DEMLOVÁ a Jiří MAYER. Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission. In 63rd ASH Annual Meeting and Exposition in Blood. 2021. ISSN 0006-4971. Dostupné z: https://doi.org/10.1182/blood-2021-146221.

@proceedings{1830798,
   author = {Žáčková, Daniela and Faber, Edgar and Stejskal, L. and Karas, M. and Bělohlávková, Petra and Klamová, H. and Černá, O. and Cmunt, Eduard and Čičátková, Petra and Semerád, Lukáš and Horňák, Tomáš and Kvetková, Anežka and Procházková, Jiřina and Rychlíčková, Jitka and Štěpánová, Radka and Svobodník, Adam and Machová Poláková, Kateřina and Ježíšková, Ivana and Jurček, Tomáš and Borský, Marek and Wiewiorka, Ondřej and Demlová, Regina and Mayer, Jiří},
   booktitle = {63rd ASH Annual Meeting and Exposition in Blood},
   doi = {https://doi.org/10.1182/blood-2021-146221},
   keywords = {Tyrosine Kinase Inhibitors' Discontinuation; Two-Step Dose Reduction; Chronic Myeloid Leukemia},
   language = {eng},
   title = {Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.},
   url = {https://ashpublications.org/blood/article/138/Supplement%201/3606/479768/Half-A-Prospective-Multi-Centre-Phase-II-Clinical},
   year = {2021}
}

TY  - CONF
ID  - 1830798
AU  - Žáčková, Daniela - Faber, Edgar - Stejskal, L. - Karas, M. - Bělohlávková, Petra - Klamová, H. - Černá, O. - Cmunt, Eduard - Čičátková, Petra - Semerád, Lukáš - Horňák, Tomáš - Kvetková, Anežka - Procházková, Jiřina - Rychlíčková, Jitka - Štěpánová, Radka - Svobodník, Adam - Machová Poláková, Kateřina - Ježíšková, Ivana - Jurček, Tomáš - Borský, Marek - Wiewiorka, Ondřej - Demlová, Regina - Mayer, Jiří
PY  - 2021
TI  - Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.
KW  - Tyrosine Kinase Inhibitors' Discontinuation
KW  - Two-Step Dose Reduction
KW  - Chronic Myeloid Leukemia
UR  - https://ashpublications.org/blood/article/138/Supplement%201/3606/479768/Half-A-Prospective-Multi-Centre-Phase-II-Clinical
N2  - Treatment-free remission (TFR) has become a new treatment goal for chronic myeloid leukemia (CML) patients. However, usually abrupt tyrosine kinase inhibitors (TKIs) therapy discontinuation has been successful only in about half of eligible patients and it can cause burdening TKI withdrawal syndrome (TWS) in about 30% of them. Moreover, any robust clinical or biological factor predictive for successful TFR has not been identified yet. On top of that, sustainable deep molecular response (DMR) as the main prerequisite for TKI discontinuation attempt is achieved only in 20-40% of patients. The majority of CML patients, therefore, need to be treated with the effective and well-tolerated drug for a long time or even life-long.
ER  -

ŽÁČKOVÁ, Daniela; Edgar FABER; L. STEJSKAL; M. KARAS; Petra BĚLOHLÁVKOVÁ; H. KLAMOVÁ; O. ČERNÁ; Eduard CMUNT; Petra ČIČÁTKOVÁ; Lukáš SEMERÁD; Tomáš HORŇÁK; Anežka KVETKOVÁ; Jiřina PROCHÁZKOVÁ; Jitka RYCHLÍČKOVÁ; Radka ŠTĚPÁNOVÁ; Adam SVOBODNÍK; Kateřina MACHOVÁ POLÁKOVÁ; Ivana JEŽÍŠKOVÁ; Tomáš JURČEK; Marek BORSKÝ; Ondřej WIEWIORKA; Regina DEMLOVÁ a Jiří MAYER. Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission. In \textit{63rd ASH Annual Meeting and Exposition in Blood}. 2021. ISSN~0006-4971. Dostupné z: https://doi.org/10.1182/blood-2021-146221.

Přehled o publikaci